Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDE100 in primary dysmenorrhea
NCT05640232Phase 3Recruiting
- Sponsor
- EMS
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hyoscine butylbromide in primary dysmenorrhea (PD), sponsored by EMS. Started Jun 2025; status: recruiting.
02
Drugs
hyoscine butylbromide
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on NCT05640232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640232.